Status:
UNKNOWN
Understanding Women's Values in Managing Human Papillomavirus (HPV)
Lead Sponsor:
University of Aberdeen
Conditions:
Human Papilloma Virus Infection
Eligibility:
FEMALE
25-64 years
Brief Summary
Almost all cervical cancers are caused by infection with a high-risk (hr) HPV. In March 2020, the Scottish Cervical Screening programme changed from a test to look for abnormal cervical cells caused b...
Detailed Description
A scoping review was conducted to determine the background information and evidence available with regards to treatment of persistent human papillomavirus (HPV) in women. This scoping review, which wi...
Eligibility Criteria
Inclusion
- Non-pregnant, English speaking, female patients aged 25-64 years
- Women with cervical high risk HPV infection
- Normal colposcopy, or, if cytological or histological changes present at colposcopy, a diagnosis of borderline nuclear abnormalities, low grade dyskaryosis or CIN1 only
Exclusion
- Cytological or histological diagnosis of CIN2+, high grade dyskaryosis, or cervical cancer at colposcopy
- Planned treatments that involve surgical excision e.g. LEEP, LLETZ, conisation or ablation of cervix
- Chronic immunosuppression
- Limited English language proficiency
Key Trial Info
Start Date :
November 6 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06123533
Start Date
November 6 2023
End Date
December 31 2024
Last Update
November 8 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.